Medac Pharma, Inc. Announces Multiple Poster Presentations During the 2013 ACR/ARHP Annual Meeting
Presentations to Highlight Data from Two Recently Completed Clinical Trials for Company’s Lead Rheumatoid Arthritis Products
CHICAGO, Oct. 21, 2013 /PRNewswire/ — Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced today that data from two recently completed clinical trials for its lead product will be presented during the 2013 American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Meeting to be held October 25 – 30, in San Diego, CA at the San Diego Convention Center.
“We’re encouraged by the data each of these studies have generated as it provides additional validation for our unique approach to delivering a broad dosing range of methotrexate to patients with rheumatoid arthritis,” remarked Terri Shoemaker, President and CEO of Medac Pharma, Inc. “Our primary goal is to provide this extremely underserved patient population with a more personalized delivery technique to managing their disease, and we believe we’re on track for accomplishing that through our unique approach.”
The posters will highlight Medac Pharma Inc.’s rationale for the development of its lead product by presenting data on relative bioavailability and ease of self-administration.
Monday, October 28, 2013:
Title: Successful Self-Administration of Methotrexate In Rheumatoid Arthritis Patients Using a Prefilled Autoinjector Pen Time: Available: 9:00 a.m. PT - 11:00 a.m. PT Poster: Abstract #1354 Location: Exhibit Hall B2-C-D (8:30 a.m. PT - 4:00 p.m. PT) Subcutaneous Administration Of Methotrexate With a Prefilled Autoinjector Pen Results In a Higher Relative Bioavailability Compared To Oral Administration Of Title: Methotrexate Time: Available: 9:00 a.m. PT - 11:00 a.m. PT Poster: Abstract # 1355 Location: Exhibit Hall B2-C-D (8:30 a.m. PT - 4:00 p.m. PT)
About Medac Pharma, Inc.
Medac Pharma, Inc. is the wholly owned subsidiary of medac GmbH, a well known and respected global pharmaceutical company that has been making scientific and therapeutic discoveries for more than 40 years.
Medac Pharma Inc. is focused on developing therapies with the potential to make meaningful differences in patients’ lives. The company’s approach is to improve existing agents by enhancing the mode of delivery, addressing safety profiles and inventing ways to maximize efficacy.
For more information, please visit www.medacpharma.com.
SOURCE Medac Pharma, Inc.